patent.fyi
Applications  /  US 2026/0355284
United States Patent Application Publication

US 2026/0355284 A1

Published
Nov 12, 2026
Filed
Jul 8, 2022
Earliest date on the face
Jul 8, 2021
Classification
A61K 38/26
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Gastric volume displacement

What ifWhat if a sealed balloon occupied part of the stomach to promote earlier fullness during meals?
Claim language“a composition comprising an agent”

An endoscopic catheter places a deflated silicone balloon in the stomach and fills it with saline. A self-sealing valve retains the fluid, and the balloon occupies gastric volume between meals.

1.1Local inhibition of fat digestion

What ifWhat if a small-molecule lipase inhibitor reduced the amount of dietary fat absorbed during a meal?
Claim language“Peptide YY (PYY)”

An oral capsule releases the inhibitor into the gastrointestinal lumen during a fat-containing meal. The inhibitor binds gastric and pancreatic lipases, reducing the breakdown of triglycerides into absorbable fatty acids and monoglycerides.

1.1Fullness through fiber hydration

What ifWhat if a hydrated soluble fiber gel promoted fullness before a meal?
Claim language“glucagon-like peptide 1 (GLP-1)”

Psyllium husk particles disperse in water and form a viscous gel as they hydrate. The hydrated fiber contributes volume to stomach contents and promotes fullness.

1.2Weekly subcutaneous peptide delivery

What ifWhat if a pen injector delivered a long-acting glucagon-like peptide 1 analog into subcutaneous tissue?
Claim language“administered intranasally, topically to the gastrointestinal (GI) tract, or intrarectally”

A prefilled pen meters a dose through a short needle into the fat layer beneath the skin. The analog enters the circulation and activates receptors involved in appetite regulation.

1.2Mealtime rise in circulating insulin

What ifWhat if a mealtime insulin dose raised the concentration of insulin in the blood to control postmeal glucose?
Claim language“without substantially changing the concentration of the agent”

A pump delivers a bolus of rapid-acting insulin through a subcutaneous cannula at mealtime. The resulting rise in circulating insulin increases glucose uptake and suppresses glucose release by the liver.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Bench testing for nasal device training

A nasal cast with a removable hydrogel liner supports training in the placement and actuation of a nasal delivery device. A peptide formulation containing a fluorescent tracer is dispensed into the cast at a marked insertion depth and angle. An imaging station records the deposit on the liner, and a peptide assay of wash samples measures the amount retained in each region.

Component substitution

Dissolving nasal film with peptide

A thin hydroxypropyl methylcellulose film replaces the liquid nasal vehicle and carries the same peptide. The peptide is mixed into an aqueous polymer solution, cast as a sheet, dried, and cut into individual strips. A placement tool presses the strip against the nasal lining, where surface moisture hydrates the film and releases the peptide.

Parameter or scale variation

Film thickness series for release testing

A bench series uses 50, 100, and 200 micrometer dry films with the same footprint and peptide mass per film. The polymer mass changes across the series to produce the three thicknesses. Each film contacts a hydrated membrane at 37 °C, and samples collected at 2, 5, 10, and 20 minutes provide a release curve for each thickness.

Combination with existing systems

Endoscopic applicator for gastric peptide delivery

A flexible endoscope carries a blunt dispensing catheter through its working channel. A syringe connected to the catheter dispenses a measured volume of peptide gel while the endoscopic camera shows the catheter tip and the gastric surface. The gel spreads over the selected surface, and the endoscope records the application site.

Local delivery with paired blood sampling

A nasal metering device is paired with timed venous blood collection and a quantitative peptide assay. The device log records each actuation, and a shared clock aligns that record with blood collection and satiety ratings during a standardized meal session. Each participant completes a peptide session and a vehicle session to provide paired measurements of circulating peptide concentration and reported satiety.

Automated or data-driven variant

Breath triggered nasal pump actuation

A motor-driven metering pump connects to a nasal nozzle, and a pressure sensor samples a separate air passage in the nosepiece. A controller detects a sustained pressure drop during inhalation and triggers one pump stroke when the signal crosses a configured threshold. The controller records the sensor trace and pump stroke and requires a manual reset before another delivery.

Specific version of a part

Buffered aqueous peptide formulation

A peptide YY formulation contains the peptide in sterile water with a phosphate buffer and sodium chloride. The buffer controls pH, and sodium chloride adjusts the tonicity of the solution.

Metered nasal spray delivery

A metering pump dispenses a fixed volume of peptide solution through a nasal spray nozzle. The nozzle disperses the liquid into droplets that deposit on the nasal mucosa.

Rectal gel delivery

A single-use applicator with a rounded tip dispenses a peptide-containing hydroxyethyl cellulose gel into the rectum. The gel spreads over the mucosa and holds the formulation at the application site.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2014/0221963 A1
Published
Aug 7, 2014
Filed
Aug 23, 2012
Class
A61M 5/1723
Document BUS 2017/0326112 A1
Published
Nov 16, 2017
Filed
Apr 27, 2017
Class
A61K 31/4164
Claim 1
Document A
Document B
1.1administering to the subject a composition comprising an agent selected from Peptide YY (PYY), glucagon-like peptide 1 (GLP-1), leptin, amylin, insulin, and calcitonin, or an analog, variant, or biologically active fragment thereof
The method of claim 1, wherein the biologically active agent is selected from a group consisting of cholecystokinin, peptide YY, glucagon-like peptide 1 or 2, and ghrelin, or a combination thereof.
A · US 2014/0221963 A1 · claim 15
1.2wherein the composition is administered intranasally, topically to the gastrointestinal (GI) tract, or intrarectally, and wherein the composition provides treatment without substantially changing the concentration of the agent in the blood of the subject.
In another aspect, the invention provides a method for anesthetizing at least a portion of a patient's maxillary dental arch (and pain fibers external to the dental arch) in a subject comprising selectively delivering into the nasal cavity of the subject a pharmaceutical composition of the invention, wherein at least a portion of the pharmaceutical composition is absorbed by nasal tissue located at the rear of the nasal cavity in the vicinity of the sphenopalatine ganglion an
B · US 2017/0326112 A1 · ¶ 22

An empty cell means only that no passage was reproduced there.

Statements in these documents
Certain conditions, such as obesity, can benefit from treatment that is delivered in conjunction with food ingestion.
A · US 2014/0221963 A1 · ¶ 6
Such agents, taken either by mouth or by injection, may be active for prolonged periods of time, including periods when food is not being consumed, such as during sleep.
A · US 2014/0221963 A1 · ¶ 6
The present invention also relates to tetracaine based dental anesthetic formulations and methods for anesthetizing the maxillary dental arch using these formulations.
B · US 2017/0326112 A1 · ¶ 2
Thus, further incentive exists to develop anesthetics that can be delivered without the use of needles and comply with U.S. federally mandated engineered work practice controls.
B · US 2017/0326112 A1 · ¶ 5
Cite aspatent.fyi, US 2026/0355284 A1, claim 1, first published 2026-11-19T09:44:02-05:00, https://patent.fyi/US20260355284/, SHA-256 c655b8afff07a07663cd8d4e7ac2e76f264730e212bc8e28e7a516fc471f3f72
First published
Permanent addresshttps://patent.fyi/US20260355284/
Content fingerprint (SHA-256)c655b8afff07a07663cd8d4e7ac2e76f264730e212bc8e28e7a516fc471f3f72
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi